Court Refuses to Hear Case on European Drug Pricing (New York Times)
Europe's highest court said Tuesday that it had no jurisdiction in a case involving the practice of buying drugs in low-priced countries within the European Union and diverting them to nations that set higher prices
よく分からないのは、次の部分が医薬品メーカー自身の"policy"なのか、何か法的な規制があるのかという点
The business has sprung from a pricing policy in Europe unique to the drug industry. Each European country sets the price that drug manufacturers charge for medicines based on how wealthy the country is. The prices drug makers set for Eastern Europe can be as much as 30 percent to 70 percent less than in Britain, for example.
単なるメーカー自身のpolicyなら、EUの経済統合の中で起こるべくして起こる裁定取引であって、あとは｢医薬品は生命にかかわるものだから特別｣、さらにいえば｢医薬品メーカーに研究開発費用を回収できるだけの利益を与える必要がある｣というロジックになるのですが。
さて、どういうことなんでしょうね？
